Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study.

ABSTRACT:

Introduction

Prednisolone is widely prescribed to hospitalized patients for a range of conditions. Up to 40% of hospitalized patients treated with prednisolone will experience hyperglycemia. Current guidelines recommend management of acute hyperglycemia in hospitalized patients with subcutaneous basal-bolus insulin (BBI), but the optimum treatment strategy has not been defined. We aimed to assess the performance of an individualized subcutaneous BBI regimen for management of prednisolone-associated hyperglycemia in hospitalized patients.

Research design and methods

This cross-sectional study included 23 adult inpatients prescribed subcutaneous BBI based on total daily insulin requirements estimated from a 24-hour intravenous insulin infusion and 24 historical controls who we

SUBMITTER: Chen AX 

PROVIDER: S-EPMC12598994 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature